Trial Profile
Efficacy/tolerability of nintedanib in clinical practice using data from a large cohort of patients treated in the German compassionate use program (CUP)
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 04 Jan 2017
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 04 Jan 2017 New trial record